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Affective computing (also referred to as artificial emotion intelligence or emotion AI)
is the study and development of systems and devices that can recognize, interpret,
process, and simulate emotion or other affective phenomena. With the rapid growth
in the aging population around the world, affective computing has immense potential
to benefit the treatment and care of late-life mood and cognitive disorders. For late-life
depression, affective computing ranging from vocal biomarkers to facial expressions
to social media behavioral analysis can be used to address inadequacies of current
screening and diagnostic approaches, mitigate loneliness and isolation, provide more
personalized treatment approaches, and detect risk of suicide. Similarly, for Alzheimer’s
disease, eye movement analysis, vocal biomarkers, and driving and behavior can provide
objective biomarkers for early identification and monitoring, allow more comprehensive
understanding of daily life and disease fluctuations, and facilitate an understanding of
behavioral and psychological symptoms such as agitation. To optimize the utility of
affective computing while mitigating potential risks and ensure responsible development,
ethical development of affective computing applications for late-life mood and cognitive
disorders is needed.
Keywords: affective computing, late-life depression, dementia, Alzheimer’s disease, digital phenotyping

INTRODUCTION
Between 2019 and 2050, the number of people aged 65 years or over in the world will increase
from 703 million to 1.5 billion people (1). With the rapid growth in the aging population
around the world, improving the standard of care in late-life mood and cognitive conditions is
of the utmost importance. Late-life mood and cognitive conditions are characterized by their
complexity, multisystemic nature and broad societal impact, hence making them poorly suited
to siloed approaches of thinking and innovation (2). Issues such as overlapping symptoms,
comorbidities, and misdiagnosis among mental health and neurological disorders represents only
a small subset of the challenges facing late-life mood and cognitive conditions (2). For example,
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(13). The scope and burden of late-life depression is significant
and expected to rise in the 21st century (14). Depression
is estimated to affect 29% of elderly Europeans (15) and
30.6% of elderly Chinese (16). When compared to younger
patients with depression, older adults with depression typically
have more medical and neurologic comorbidities and display
more cognitive impairment (17). Data suggest that 1 in 10
cases of dementia world-wide can be attributed to depression
(18). Neurotoxicity due amyloid and tau protein aggregation
may represent a pathophysiological cascade which, along with
vascular compromise, may predispose individuals to late-life
depression (17). Table 1 highlights clinical challenges in latelife depression and ways in which affective computing may
be beneficial.
Williamson et al. (23) examined changes in motor output
in people with depression from vocal acoustics and facial
movements (23). Using the 4th International Audio/Video
Emotion Challenge (AVEC), which consists of a read passage
and free-response speech segment from subjects with varying
depression levels according to their self-reported Beck depression
inventory assessment, they developed a multimodal analysis
pipeline that leverages complementary information in audio
and video signals including structure and timing features for
estimating depression severity. Using the identified features of
changes in coordination, movement, and timing of vocal and
facial movements, the developed algorithm was able to predict
the Beck depression inventory ratings from the AVEC test set
with a root-mean-square error of 8.12 and mean absolute error
of 6.31 (23).
De Choudhury et al. (36) used behavioral attributes from
social media to characterize severity of depression at a population
level by developing a social media depression index (SMDI) (73).
Using crowdsourcing techniques, they built a corpus of over 69K
Twitter postings shared by individuals diagnosed with clinical
depression that was measured using the Center for Epidemiologic
Studies Depression Scale (CES-D) screening test. By analyzing
behavioral features including emotional expression, linguistic
style, user engagement, and egocentric social network properties,
they built a model that can predict if a post is indicative of
depression with an accuracy of more than 70% and precision
of 0.82. Lastly, they developed the SMDI metric. The SMDI
metric leverages the prediction model to predict posts indicative
of depression on Twitter and helps characterize the levels of
depression in populations. The geographical, demographic, and
seasonal patterns of depression given by SMDI confirm known
clinical characteristics of depression and are highly correlated
with depression statistics reported by the Centers for Disease
Control and Prevention (CDC) (73).
Mundt et al. (42) used vocal acoustic biomarkers to predict
depression severity and treatment response (42). One hundred
five adults with depression were recruited into a 4-week,
randomized, double-blind, place-controlled clinical trial. Speech
samples were collected at baseline and study end point using
an automated telephone system. Clinician-rated and patientreported measures of depression severity and treatment response
were collected. Results from the study replicated and supported
findings from prior studies. More severe depression produced

psychiatric symptoms often occur during prodromal stages of
neurodegenerative diseases (3–5). Neurodegenerative diseases
are often misclassified as psychiatric disease, which can cause
the patient to receive delayed, inappropriate treatment and
experience more distress (4). Relatedly, many neurodegenerative
conditions have clinical and neuropathological overlap, which
can cause difficulty with accurate diagnosis and treatment
(6). Comorbidities also present further challenges. As an
example, 61% of people with dementia are estimated to have
three or more comorbid diagnoses (7), which often remain
over or under-treated and negatively affect the physical and
psychological well-being of people with dementia (8). As the
burden of late-life mood and cognitive disorders continues to
rise, improved prevention, diagnosis, and treatment options
are urgently needed (9, 10). To solve the unprecedented
complexities and challenges associated with late-life mood
and cognitive conditions, new technologies and approaches to
care are needed. Affective computing has immense potential
to benefit the treatment and care of late-life mood and
cognitive disorders. Affective computing (also referred to as
artificial emotion intelligence or emotion AI) is the study
and development of systems and devices that can recognize,
interpret, process, and simulate emotion or other affective
phenomena (11, 12). It is a transdisciplinary field that combines
engineering and computer science with psychology, cognitive
science, neuroscience, sociology, education, psychophysiology,
value-centered design, ethics, and more.
In this paper, we aim to provide an overview of common
affective computing modalities with applications for late-life
mood and cognitive disorders. We additionally explore specific
applications for late-life depression and Alzheimer’s disease
(AD). Lastly, we discuss ethical implications and analyze
key challenges that must be overcome to ensure ethical
development of affective computing for late-life mood and
cognitive conditions.

METHODS
Publications were collected in September 2021 from four
databases: PubMed, PsycINFO, OvidSP, and Web of Science.
To construct the search protocol, the research question was
structured in terms of the following topics: Affective Computing,
digital phenotyping, late-life depression, dementia, Alzheimer’s
disease, and ethical issues. Synonyms and main terms for these
topics were selected to construct the search codes. After an initial
search, publication titles and abstracts were screened according
to year of publication, publication in English language, and
of peer-reviewed type. A total of 150 articles were utilized in
this review.

RESULTS
Affective Computing and Late-Life
Depression
Depression is the leading cause of disability worldwide and
a major contributor to the overall global burden of disease
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TABLE 1 | Affective computing applications for clinical challenges in late-life depression.

APPROACHES FOR AFFECTIVE COMPUTING IN CLINICAL CHALLENGES OF LATE-LIFE DEPRESSION
Use facial expression
biomarkers to detect
depression (23–30)

Use head movements and Use gaze and eye
pose to detect depression movement to detect
(26, 30–32)
depression to detect
behavioral consistent
with depression (33)

Use keystroke dynamics
to detect typing
behavior associated
with depression (34)

Use behavioral attributes
related to social engagement,
emotion, language, linguistic
style, and writing aspects to
detect depression (35–40)

Use SARs to administer
screening and diagnostic
approaches that leverage
affective computing
biomarkers (41)

Trial-and-error
treatment
approaches

Monitor depression
severity and treatment
response to determine
optimal treatment using
vocal biomarkers (42–45)

Monitor depression
severity and treatment
response to determine
optimal treatment using
facial expression
biomarkers (46)

Leverage body and head
movement analysis to
measure depression
severity throughout the
course of treatment to
determine optimal
approach (46, 47)

Measure depression
treatment response
using anti-saccade eye
movement tasks (48)

Determine optimal
treatment by measuring
depression severity via
touchscreen typing (49)

Assess social media behavior
and develop treatment strategy
for social media usage that
reinforces depressive beliefs
and symptoms to improve
overall treatment outcomes
(50)

Use SARs to provide
in-home therapeutic
approach and collect
real-time data on affective
computing biomarkers to
determine optimal
treatment strategies (41)

Loneliness and Detect loneliness and
social isolation social isolation and better
identify behavioral
phenotypes of loneliness
and social isolation
through vocal biomarkers
(51)

Assess spontaneous
smile mimicry to detect
and monitor loneliness
(52)

Assess body movement
coordination, which may
be impaired during
loneliness due to changes
in the left posterior
superior temporal sulcus
(53)

Assess eye movement,
which may be impaired
during loneliness due to
changes in the left
posterior superior
temporal sulcus (53)

Assess keystroke
dynamics and hand
action, which may be
impaired during
loneliness due to
changes in the left
posterior superior
temporal sulcus (53)

Monitor social media behavior
for early detection of loneliness
(54)

Use socially assistive
robots (SARs) or social
companion robots that
have affective computing
capabilities to help older
adults with depression
(55–57)

Poor treatment Monitor daily fluctuations
follow-up
using vocal biomarkers
during time outside of the
clinic and receive alerts if
problems with treatment
(19, 23)

Monitor daily fluctuations
using facial expression
biomarkers during time
outside of the clinic and
receive alerts if problems
with treatment (23)

Assess body movement
during time outside of the
clinic to better understand
symptom fluctuations
(46, 47)

Track eye movement to
understand depression
symptoms between
in-clinic visits (48)

Monitor keystroke
behavior to assess
treatment efficacy (34)

Monitor behavioral attributes
related to social engagement,
emotion, language, linguistic
style, and writing aspects to
monitor depression symptom
severity between treatment
sessions or clinic visits (35–40)

Use SARs to interact with
older adults and
understand depression
symptom progression and
severity (55–57)

Co-occurrence Differentiate between
depression and anxiety
with anxiety
disorders using vocal
disorders
biomarkers

Differentiate between
depression and anxiety
disorders using facial
expression biomarkers

Identify and monitor
anxiety and depression
severity scores using
digital gait movement (58)

Assess anxiety and
depression severity
using eye movement
(59)

Monitor and differentiate
between anxiety and
depression via
touchscreen typing (34)

Detect anxiety and depression
via social media behavior (40)

Capture affective
computing biomarkers to
differentiate between
anxiety and depression via
SARs (41)

Co-occurrence
with
Alzheimer’s
disease

Monitor symptoms
associated with
depression and
Alzheimer’s disease using
vocal biomarkers (60)

Monitor symptoms
associated with
depression and
Alzheimer’s disease using
facial expression
biomarkers (61)

Kinematic analysis can
detect co-morbid
Alzheimer’s disease for
patients with depression
(62)

Detect and differentiate
between Alzheimer’s
and depression via eye
movement tracking
(63, 64)

Monitor early stages of
Alzheimer’s disease and
depression via
touchscreen typing
(34, 65)

Detect late-life depression in
Alzheimer’s disease patients
via speech and language
analysis on social media (66)

Use SARs to analyze
speech and language of
people with late-life
depression and Alzheimer’s
disease (66)

Risk of suicide

Detect suicidal ideation
and risk using vocal
biomarkers (67)

Evaluate risk of suicide
using facial expression
biomarkers (68)

Monitor body movement
to detect risk of suicide
(69)

Assess eye movement
to identify attention bias
for suicide related stimuli
(70)

Use digital phenotyping
from smartphone typing
to detect risk of suicide
(69)

Detect suicidal ideation and
risk using social media
behavioral analysis (71, 72)

For people at risk of
suicide, SARs can be
leveraged to track affective
computing biomarkers that
indicate risk of suicide (69)
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adults (95). Fifty-five adults (11 with MCI and 44 cognitively
normal) were tested on two occasions. During the first visit,
participants underwent a brief eye-tracking based visual pairedcomparison (VPC), Montreal Cognitive Assessment (MoCA),
Digital Symbol Coding test (DSC), and NIH Toolbox Cognitive
Battery (NIHTB-CB). During the second visit, participants
underwent VPC, DSC, NIHTB-CB, and dual-task (DT). VPC
reliably predicted cognitive status while demonstrating high testretest reliability and displayed significant associations with gold
standard cognitive assessments (95). Eye-tracking based VPC
may provide a useful, brief, and scalable screening tool for
cognitive impairment (95).

longer recordings with more pause time, more variable pause
lengths, a greater percentage of pause time, smaller speech/pause
ratios, and slower speaking rates. Speech pause times were found
to shorten with clinical improvement following treatment, and
depressed patients who did not improve clinically were found
to have smaller vocal acoustic changes and/or changes that were
directionally opposite to treatment responders.

Affective Computing and Alzheimer’s
Disease
Alzheimer’s disease (AD) is the most common neurodegenerative
disorder and largest cause of dementia in the world with rapidly
growing personal, societal, economic, and medical implications.
In the United States alone, over 6.2 million people suffer from AD
that costs the healthcare system more than $355 billion annually,
not including the value of informal caregiving (74). At a global
level, there are more than 35 million people currently living with
AD, and by 2050 the number is expected to more than triple,
exceeding 115 million people (75). There is growing interest in
detecting AD during prodromal stages because (a) the likelihood
of reversing anatomic and physiologic changes (such as neuronal
death) likely decreased dramatically as the disease advances
(61, 76), (b) there is a growing body of evidence that cognitive,
sensory, and motor changes may precede clinical manifestation
of AD by 10–20 years (74, 76), and (c) aducanumab, the only
approved disease-modifying therapy is recommended only for
patients with early AD (77). Table 2 highlights clinical challenges
in AD and ways in which affective computing may be beneficial.
Ahmed et al. (83) examined connected speech as a marker
of disease progression in autopsy-proven AD (83). Samples
of connected speech were obtained from 15 patients who
were part of a longitudinal cohort study in whom AD was
diagnosed during life and later confirmed at post-mortem. The
study analyzed spoken discourse over the course from MCI to
mild AD dementia to moderate AD dementia. Samples were
analyzed using measures of syntactic complexity, lexical content,
speech production, fluency, and semantic content. Subtle changes
were found in spoken language that were detectable in MCI
stages and enabled monitoring progression through successive
clinical stages of AD. Language biomarkers could help identify
prodromal AD and provide a way to monitor disease in
therapeutic trials (83).
Bayat et al. (113) evaluated the ability of in-vehicle GPS data
loggers and driving behavior to distinguish cognitively normal
older drivers with preclinical AD from those without preclinical
AD using machine learning algorithms (113). For 1 year, 139
subjects (64 with preclinical AD; 75 without preclinical AD, as
determined by cerebrospinal fluid biomarkers) were monitored
while they drove with a commercial in-vehicle GPS data logger.
Random Forest models were trained on the GPS data. The
receiver operating curve (ROC) area under the curve (AUC) for
predicting preclinical AD from driving features alone was 0.82,
with the addition of age alone increased to 0.94, and with the
additions of age and APOE ε4 status increased to 0.96 (113).
Gills et al. (95) developed and validated a short digital
eye-tracking assessment that predicts cognitive status among

Frontiers in Psychiatry | www.frontiersin.org

Ethical Implications of Affective
Computing in Healthcare
New approaches are needed to address the technical, scientific,
philosophical, and ethical challenges associated with affective
computing applications in healthcare (114). One key challenge
is ensuring that the tools account for sex, gender, racial, ethnic,
and culture-based differences. For example, two-thirds of AD
patients worldwide are women (115, 116). Women have a higher
lifetime risk of stroke than men, and women are twice as
likely to be diagnosed with depression and anxiety disorders,
and migraines (116–118). These are all specific risks factors for
developing dementia.
Given the higher rate of depression and AD among women
research is needed to understand if and how sex and genderbased differences affect disease manifestations that may result
in the need for different digital biomarkers and machine
learning affective computing approaches for males vs. females.
It is critical to ensure that the machine learning algorithms
capture symptoms that may be more common or different
in females.
We must ensure that algorithmic fairness with affective
computing does not stop at merely accounting for sex and
gender-based differences. Data sets and algorithms used for
affective computing must also include bias reduction measures
that account for ethnic, racial, geographical, cultural, and other
human biases (119). As one example, facial analysis algorithms
are often trained on datasets that are predominately comprised
of lighter-skinned males and may fail to detect female faces
and people of different races and ethnicities (120). Algorithmic
and human bias must be addressed to ensure greater fairness,
transparency, and accountability in the development of affective
computing applications.
The various ways affective computing can be leveraged in
healthcare also have different ethical implications. For example,
current affective computing technologies typically leverage
passive or active data collection. In the context of affective
computing for healthcare, passive data collection may entail
information continuously collected from smartphone usage,
driving, or social media, whereas active data collection may
involve specific vocal or facial expression assessments within
a clinical setting. Different ethical and practical considerations
arise for passive vs. active data collection and the setting in which
data is conducted (e.g., at home using everyday technological
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TABLE 2 | Affective computing applications for clinical challenges in AD.
Vocal biomarkers

Facial expression
biomarkers

Body movements

Eye movements

Keystroke dynamics

APPROACHES FOR AFFECTIVE COMPUTING IN CLINICAL CHALLENGES OF ALZHEIMER’S DISEASE
Lack of early, objective
screening and diagnostic
approaches

Use vocal biomarkers to
detect and access mild
cognitive impairment (MCI)
and prodromal stages of
AD (61, 78–83)

Assess cognitive and
neuropsychiatric
symptoms of AD using
facial expression
impairments (84, 85)

Capture motor
impairments that precede
signs of cognitive
impairment by over a
decade in people with AD
through measuring gait
speed, stride length, and
gait symmetry (61, 86–90)

Use eye movement to
Capture differences in
detect MCI and prodromal reaction speed and
stages of AD (91–95)
movement that have been
found in early stages of
AD using an active finger
tapping test or passive
data collection from daily
computer, tablet, or
smartphone keyboard use
(61, 96–98)

Lack of objective
biomarkers for monitoring
disease progression and
comprehensive, daily
fluctuations

Use vocal biomarkers to
monitor disease
progression (83)

Monitor diseases
progression and daily
fluctuations of symptoms
using facial expressions
(84, 85)

Assess gait and balance
throughout AD to monitor
disease progression
(99–101)

Monitor eye movement to
track AD progression
(102, 103)

Monitor progression of
cognitive impairment
including MCI to AD using
touchscreen typing
(61, 65)

Understanding and
addressing the behavioral
and psychological
symptoms, such as
agitation and pain,
experienced by patients
with AD

Capture vocal biomarkers
using sensing technology
to monitor behavioral and
psychological symptoms
of AD (104)

Digitize facial expressions
and movements to
monitor behavioral and
psychological symptoms
of AD using sensing
technology (104)

Use body movements,
such as number of
transitions between
spaces, to detect and
better understand different
behavioral and
psychological symptoms
of AD (105)

Use eye movements to
understand and monitor
behavioral and
psychological symptoms
of AD via sensing
technology (104)

Analyze typing to identify
subtypes of AD based on
the presence and intensity
of behavioral and
psychological symptoms
of AD

Co-occurrence with
depression

Monitor symptoms
associated with
depression and AD using
vocal biomarkers (60)

Monitor symptoms
associated with
depression and AD using
facial expression
biomarkers (61)

Kinematic analysis can
detect co-morbid AD for
patients with depression
(62)

Detect and differentiate
between AD and
depression via eye
movement tracking
(63, 64)

Monitor early stages of AD
and depression via
touchscreen typing
(34, 65)

Misdiagnosis between AD
and other
neurodegenerative
disorders during early
stages of disease
progression

Differentiate between AD,
Parkinson’s disease (AD),
and Lewy Body Disease
(LBDs) using vocal
biomarkers (60, 106–109)

Differentiate between AD
and PD using facial
expression analysis

Differentiate between AD
and PD using digital gait
analysis (99–101, 110)

Assess PD, AD, and Lewy Detect and differentiate
body dementia via eye
early stages of PD and AD
movement analysis (111)
using typing and keyboard
dynamics (61, 65, 112)

intelligence that is responsive and sustainable (121). These
ethical principles must guide the development of affective
computing applications for late-life mood and cognitive
conditions to ensure human rights are upheld and that patient
and community interests do not become subordinate to the
powerful commercial interest of technology companies or the
interests of governments in surveillance and social control (121).
Questions related to data security, privacy, and ownership must
also be addressed; how CAN these concerns be navigated on a
global scale? Initiatives such as the National Institute of Health
Bridge to Artificial Intelligence (Bridge2AI) program brings
together technologists, biomedical experts, social scientists, and
humanists to develop ethical data sets and tools and will help
navigate these pressing questions related to affective computing
applications in brain health (122).
By addressing the ethical implications and challenges during
early stages of technology development, the introduction of
affective computing technology in healthcare can bring a new
era of health that is marked by a proactive, personalized, and
preventative approach to care. Affective computing has the

devices or via a specific assessment in-clinic). These challenges
must be addressed.
Other ethical considerations that will need to be addressed and
mitigated with the advent of affective computing applications in
healthcare are (a) addressing privacy and data security concerns;
b) determining what it means for people and society to know
they have a disorder 10–20 years before clinical manifestations
(such as with AD or PD); (c) navigating how to update affective
computing models after deployment to make them optimally
adaptive and effective; and (d) considering what privacy means
when a doctor or friend or family member could tell if you have
a certain health condition or are suicidal.
The 2021 “Ethics and governance of artificial intelligence
for health: WHO guidance” report by the World Health
Organization (WHO) highlights key ethical principles for the use
of artificial intelligence in healthcare, which include protecting
autonomy; promoting human well-being, human safety and
the public interest; ensuring transparency, explainability and
intelligibility; fostering responsibility and accountability;
ensuring inclusiveness and equity; and promoting artificial
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progression, and more comprehensively understanding the daily
life of patients. To leverage affective computing to increase global
brain health equity and a precision medicine approach to care,
efforts are needed to ensure ethical development of affective
computing for late-life mood and cognitive conditions that
account for algorithmic and human bias. With these safeguards
affective computing can become a major tool of care of late life
affective and cognitive disorders.

possibility to be applied globally, such as through the ubiquity
of smartphones, and can help address challenges related to
health equity. Affective computing technology has the potential
to improve early detection and screening, disease severity and
progression monitoring, treatment efficacy monitoring, and the
quality of life for people around the world with a myriad of
different neurological health conditions.

CONCLUSION
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Affective computing can address challenges associated with
late-life mood and cognitive conditions, including depression
and AD. Affective computing technologies- ranging from vocal
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early detection, monitoring treatment response, tracking disease
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